Our results indicate that for antitumor activity to be exerted by anti-PD-L1 treatment, not only must the suppressed T cell priming be released but also a tumor environment necessary to attract activated T cells from the blood must be present at baseline. The gene discussed is CD274; the disease is neoplasm.